Liminatus Pharma, Inc. Class A Common Stock
$3.48
Market Cap
$4.67M
Shares Outstanding
1.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
May 1, 2025
Round Lot
100
Locale
US
Day Open
$3.43
Day High
$3.67
Day Low
$3.41
Volume
23.3K
VWAP
$3.53
Prev Close
$3.39
Transactions
--
Acc. Volume
--
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
Liminatus Pharma, Inc. Class A Common Stock (LIMN) closed the 2026-09-18 session at $3.48, up 2.65% versus the previous close (+0.09). The stock opened at $3.43 and traded between $3.41 and $3.67 during that session. Session trading volume was 23K shares. The volume-weighted average price (VWAP) is $3.53.
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
Liminatus Pharma, Inc. Class A Common Stock has a market capitalization of $4.7 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. LIMN is listed on the XNAS exchange. The company employs approximately 1 people. Liminatus Pharma, Inc. Class A Common Stock is headquartered in CERRITOS, CA. The recorded listing date is 2025-05-01.
On this page you can find market LIMN stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.